[go: up one dir, main page]

MX2018001465A - Nuevos anticuerpos anti-gpvi humana y sus usos. - Google Patents

Nuevos anticuerpos anti-gpvi humana y sus usos.

Info

Publication number
MX2018001465A
MX2018001465A MX2018001465A MX2018001465A MX2018001465A MX 2018001465 A MX2018001465 A MX 2018001465A MX 2018001465 A MX2018001465 A MX 2018001465A MX 2018001465 A MX2018001465 A MX 2018001465A MX 2018001465 A MX2018001465 A MX 2018001465A
Authority
MX
Mexico
Prior art keywords
novel anti
human gpvi
gpvi antibodies
antibodies
human
Prior art date
Application number
MX2018001465A
Other languages
English (en)
Inventor
Jandrot-Perrus Martine
Billiard Philippe
Original Assignee
Acticor Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acticor Biotech filed Critical Acticor Biotech
Publication of MX2018001465A publication Critical patent/MX2018001465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados anti-GPVI humana y usos de los mismos.
MX2018001465A 2015-08-05 2016-08-05 Nuevos anticuerpos anti-gpvi humana y sus usos. MX2018001465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179908 2015-08-05
PCT/EP2016/068778 WO2017021539A2 (en) 2015-08-05 2016-08-05 Novel anti-human gpvi antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018001465A true MX2018001465A (es) 2019-01-31

Family

ID=53836426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001465A MX2018001465A (es) 2015-08-05 2016-08-05 Nuevos anticuerpos anti-gpvi humana y sus usos.

Country Status (23)

Country Link
US (2) US10842870B2 (es)
EP (2) EP4091628A1 (es)
JP (2) JP7076082B2 (es)
KR (1) KR102751174B1 (es)
CN (2) CN108289939B (es)
AU (1) AU2016301969B2 (es)
BR (1) BR112018002382A8 (es)
CA (1) CA2994629A1 (es)
CY (1) CY1125400T1 (es)
DK (1) DK3331553T3 (es)
ES (1) ES2923677T3 (es)
HR (1) HRP20220910T1 (es)
HU (1) HUE059655T2 (es)
IL (1) IL257323B2 (es)
LT (1) LT3331553T (es)
MX (1) MX2018001465A (es)
PL (1) PL3331553T3 (es)
PT (1) PT3331553T (es)
RS (1) RS63482B1 (es)
SI (1) SI3331553T1 (es)
SM (1) SMT202200317T1 (es)
WO (1) WO2017021539A2 (es)
ZA (1) ZA201800804B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016301969B2 (en) 2015-08-05 2022-10-06 Acticor Biotech Novel anti-human GPVI antibodies and uses thereof
SG11201906530TA (en) * 2017-02-03 2019-08-27 Acticor Biotech Inhibition of platelet aggregation using anti-human gpvi antibodies
EP3793596A1 (en) * 2018-05-16 2021-03-24 MorphoSys AG Antibodies targeting glycoprotein vi
WO2021250026A1 (en) * 2020-06-08 2021-12-16 Acticor Biotech Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
CN118043349B (zh) * 2021-06-11 2024-11-15 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
US20250051452A1 (en) 2021-09-07 2025-02-13 Etablissement Francais Du Sang Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
EP4431526A1 (en) * 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
EP4556492A1 (en) 2023-11-14 2025-05-21 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1538165A1 (en) * 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
EP1745076B1 (en) 2004-04-29 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1876240B1 (en) 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
MA33930B1 (fr) * 2009-12-18 2013-01-02 Sanofi Sa Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci
PH12014500384A1 (en) * 2011-09-01 2014-04-14 Eisai R And D Man Co Ltd Anti-human xcr1 antibodies
AU2016301969B2 (en) 2015-08-05 2022-10-06 Acticor Biotech Novel anti-human GPVI antibodies and uses thereof

Also Published As

Publication number Publication date
JP7076082B2 (ja) 2022-05-27
US20180236071A1 (en) 2018-08-23
RS63482B1 (sr) 2022-09-30
HUE059655T2 (hu) 2022-12-28
IL257323B1 (en) 2023-09-01
KR20180068952A (ko) 2018-06-22
WO2017021539A2 (en) 2017-02-09
JP2022025033A (ja) 2022-02-09
PL3331553T3 (pl) 2022-09-12
ZA201800804B (en) 2023-12-20
US20200384106A1 (en) 2020-12-10
JP7277689B2 (ja) 2023-05-19
CN115925935A (zh) 2023-04-07
NZ739560A (en) 2024-01-26
CA2994629A1 (en) 2017-02-09
HK1256816A1 (en) 2019-10-04
US10842870B2 (en) 2020-11-24
IL257323B2 (en) 2024-01-01
DK3331553T3 (da) 2022-08-01
BR112018002382A2 (pt) 2019-04-16
CN108289939B (zh) 2022-08-12
WO2017021539A3 (en) 2017-03-16
EP4091628A1 (en) 2022-11-23
HRP20220910T1 (hr) 2022-10-28
RU2018107409A3 (es) 2020-01-30
PT3331553T (pt) 2022-07-27
KR102751174B1 (ko) 2025-01-07
LT3331553T (lt) 2022-09-12
AU2016301969B2 (en) 2022-10-06
SMT202200317T1 (it) 2022-09-14
JP2018526990A (ja) 2018-09-20
EP3331553B1 (en) 2022-06-29
EP3331553A2 (en) 2018-06-13
BR112018002382A8 (pt) 2022-12-06
IL257323A (en) 2018-03-29
SI3331553T1 (sl) 2022-11-30
ES2923677T3 (es) 2022-09-29
CN108289939A (zh) 2018-07-17
RU2018107409A (ru) 2019-09-05
CY1125400T1 (el) 2025-05-09
AU2016301969A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017500982A1 (en) Heterodimeric antibodies that bind cd3 and cd38
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12017502180A1 (en) Tau-binding antibodies
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
PH12016501763A1 (en) Multispecific antibodies
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
NZ749292A (en) Compositions and methods related to engineered fc constructs
PH12017502207A1 (en) Tau-binding antibodies
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
ZA201703510B (en) Antibodies, uses & methods
HK40111469A (zh) 人源化或嵌合cd3抗体
HK1255635A1 (zh) 人源化或嵌合的cd3抗体